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Identification and characterization of survival pathways active in tumor cells but absent in normal tissues provide opportunities
to develop effective anticancer therapies with reduced toxicity to the patient. We show here that, like kinase suppressor of Ras 1
(KSR1), EPH (erythropoietin-producing hepatocellular carcinoma) receptor B4 (EPHB4) is aberrantly overexpressed in human
colon tumor cell lines and selectively required for their survival. KSR1 and EPHB4 support tumor cell survival by promoting the
expression of downstream targets, Myc and the transcriptional coactivator peroxisome proliferator-activated receptor gamma
coactivator 1 (PGC1). While KSR1 promotes the aberrant expression of Myc and the PGC1 protein via a posttranscriptional
mechanism, EPHB4 has a greater effect onMyc and PGC1 expression via its ability to elevate mRNA levels. Subsequent analysis
of the posttranscriptional regulation demonstrated that KSR1 promotes the translation of Myc protein. These findings reveal
novel KSR1- and EPHB4-dependent signaling pathways supporting the survival of colorectal cancer cells through regulation of
Myc and PGC1, suggesting that inhibition of KSR1 or EPHB4 effectors may lead to selective toxicity in colorectal tumors.
Colorectal cancer (CRC) is the third most common cancer inthe United States and worldwide (1). It is sporadic in nature,
with only 15 to 30% having a major hereditary component (2, 3).
CRC is a heterogeneous disease, with distinct molecular features
of the tumor contributing to the prognosis and response to tar-
geted therapies (4). Several critical genes and pathways are impor-
tant in the initiation and progression of CRC, most notably the
Wnt, RAS/mitogen-activated protein kinase (MAPK), phosphati-
dylinositol 3-kinase (PI3K), transforming growth factor  (TGF-
), p53, and DNA mismatch repair pathways (5). Oncogenic Ras
mutations commonly occur in human CRC, with approximately
43% of patients harboring activating KRAS mutations (6). Pa-
tients carrying an oncogenic form of Ras have poorer prognoses
than patients harboring wild-type Ras (7–9). Their poor response
to therapy can be attributed to the observed attenuation in benefit
from anti-epidermal growth factor receptor (anti-EGFR) thera-
pies (10) or resistance to RAF inhibitor therapies (11). Ras pro-
teins are a family of small GTPases that regulate a number of
cellular signaling pathways associated with the promotion of an
oncogenic phenotype, particularly through the MAPK and PI3K
pathways (12). The MAPK signaling pathway is composed of the
downstream signaling molecules RAF, MEK, and extracellular sig-
nal-regulated kinase (ERK), whose subcellular locations are mod-
ulated by kinase suppressor of Ras 1 (KSR1) (13). KSR1 is a scaf-
fold of the RAF/MEK/ERK kinase cascade and is required for
maximal MAPK-dependent signaling (14, 15). While KSR1 is re-
quired for the survival of CRC cells, it is dispensable in normal
colon epithelial cells (16). KSR1/ mice develop normally with
attenuated ERK signaling and display a reduced tumor burden in
a polyomavirus middle-T-antigen-driven mouse tumor model
(17, 18). Given that KSR1 is dispensable for normal cells but indis-
pensable for colorectal cancer cells, we sought to detect and exploit
further vulnerabilities in human colon tumor cells. To do this, we
developed a gene expression-based high-throughput screen and
used functional signature ontology (FUSION) (16, 19) to identify
functional analogs of KSR1. From this screen, we identified EPH
(erythropoietin-producing hepatocellular carcinoma) receptor
B4 (EPHB4) as a KSR1-like, cancer-specific vulnerability that may
be exploited by targeted therapies.
EPH receptors are the largest family of receptor tyrosine ki-
nases (RTKs), with important roles in tissue organization and
growth during development, as well as in tissue homeostasis in
adults (20–22). Humans have nine EPHA and five EPHB receptors
that are classified by their ability to bind their respective ligands,
ephrin (EPH-receptor-interacting protein) A and ephrin B, on an
adjacent cell. There are five type A and three type B ephrin ligands.
Ephrin B ligands are transmembrane, and the receptor-ligand
binding is capable of transmitting both forward (through the
RTK) and reverse (via the ligand) signaling (reviewed in refer-
ences 23 and 24). This bidirectional signaling results in repulsion
between the two cells and is responsible for establishing boundar-
ies between distinct cell types (25, 26). For example, EPHB4 bind-
ing to its ligand, ephrin B2, contributes to the establishment of
capillaries in the vasculature, with EPHB4 expressed primarily in
the venous endothelium and ephrin B2 in the arterial endothe-
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lium (27, 28). EPHB4 or ephrin B2 knockout mice are embryonic
lethal due to their inability to develop proper vasculature systems
(29–31). In the intestine and colon, EPHB-expressing cells are pres-
ent in the progenitor cells of the crypts, whereas the ephrin B ligand is
present in the more differentiated cells (28, 32). The repulsion of
EPH-ephrin binding leads to opposing gradients and contributes to
the morphology of the intestine and colonic crypts (28, 32).
We have recently shown that tumor-specific expression of per-
oxisome proliferator-activated receptor gamma coactivator 1
(PGC1) is required for colon cancer survival (16). Previous work
has shown that PGC1 is a direct downstream target of Myc (33,
34). Myc-dependent PGC1 transcription is inhibited by hypoxia
in renal clear-cell carcinoma due to induction of MXI1 (a repres-
sor of Myc activity) (34), a mechanism that may be operative in
the hypoxic regions of many tumor types. In breast cancer cells,
HER2 and insulin-like growth factor 1 (IGF1) signaling regulate
PGC1 via induction of Myc mRNA and/or regulation of Myc
protein stability. Tight regulation of Myc expression is essential
for normal cell function (35, 36). However, in cancer cells, Myc
activation can be induced through constitutive activation of a
pathway (i.e., Wnt activation in tumors with APC mutations) (37)
or through alterations of the Myc gene (i.e., amplification and
translocation) (38, 39). Defects in the APC pathway occur in many
human colon carcinomas and result in enhanced TCF-dependent
transcriptional activation of Myc (37). In fact, Myc is essential for
the for the “crypt progenitor cell-like” phenotype of APC-defi-
cient cells in vivo (32).
Here, we examined EPHB4 and its relationship to Myc and
downstream effectors of KSR1 signaling to identify pathways on
which colorectal cancer cells are uniquely dependent. We show
that EPHB4 has phenotypic and molecular effects in colorectal
cancer cells similar to those of KSR1 and that both KSR1 and
EPHB4 are essential for the survival of colorectal cancer cells but
dispensable for survival of nontransformed immortalized human
colonic epithelial cells (HCECs). Additionally, we demonstrate
that both molecules support the expression of PGC1, which is
required for maintaining tumor cell viability. Finally, we show
that EPHB4 supports Myc expression by elevating Myc mRNA,
while KSR1 promotes the expression of PGC1 by enhancing the
translation of Myc mRNA into protein.
MATERIALS AND METHODS
Gene expression-based high-throughput screen and functional signa-
ture ontology analysis. The gene expression-based high-throughput
screen has been described previously (16, 19). The gene expression-based
signature measured in the screen is based on six genes (ACSL5, BNIP3L,
ALDOC, LOXL2, BNIP3, and NDRG1 genes) that are consistently af-
fected by KSR1 depletion, as well as two housekeeping genes (PPIB and
hypoxanthine phosphoribosyltransferase [HPRT] genes) that were in-
cluded for normalization. To identify targets that are KSR1 functional
analogs based on their gene expression-based signatures, two similarity
metrics were employed, Euclidean distance (ED) and Pearson correlation
(PC). KSR1-depleted positive controls cluster with a low ED and a high
PC. Linear regression analysis was used to establish a cutoff (PC 0.25
ED  0.5) for KSR1 similarity based on the ED and PC values of KSR1-
positive controls. Targets that clustered with the positive-control KSR1-
depleted wells and exceeded the established cutoff based on these two
metrics were designated possible KSR1 functional analogs and candidates
for further evaluation.
Cell culture. The colorectal cancer cell lines HCT116, SW480, DLD1,
SK-CO-1, Caco2, and HCT15 were purchased from the American Type
Culture Collection (ATCC). The CBS and GEO colorectal cancer cell lines
were gifts from Michael Brattain (University of Nebraska Medical Cen-
ter). The cells were grown in either Dulbecco’s modified Eagle’s medium
(DMEM) or Eagle’s minimum essential medium with 10% fetal bovine
serum (FBS), 2 mM L-glutamine, and 0.1 mM nonessential amino acids
(NEAA). All colorectal cancer cells were grown at 37°C with ambient O2
and 5% CO2. Immortalized nontransformed human colonic epithelial
cell (HCEC) lines were a gift from J. Shay (University of Texas [UT]
Southwestern) (40). HCECs were grown in medium composed of 4 parts
DMEM to 1 part medium 199 (Sigma-Aldrich) with 2% cosmic calf serum
(GE Healthcare), 25 ng/ml EGF, 1 g/ml hydrocortisone, 10 g/ml insu-
lin, 2 g/ml transferrin, 5 nM sodium selenite, and 50 g/ml gentamicin
sulfate. HCECs were grown in a hypoxia chamber with 2% O2 and 5%
CO2 at 37°C.
siRNA transfections. Pooled or individual (Table 1) small interfering
RNAs (siRNAs) targeting EPHB4 (M-003124-02), KSR1 (LU-003570-00-
0002), or Myc (L-003282), as well as a nontargeting siRNA control (D-
001810-01) (DharmaconGE), were introduced into the HCT116 or Caco2
cells using the Lipofectamine RNAiMax (Invitrogen) reverse-transfection
protocol. Briefly, 125 pmol of siRNA and 7 l of RNAiMax were com-
bined in Opti-MEM for 5 min. DNA-Lipofectamine complexes were
overlaid with 2 ml of cells (150,000 cells/ml) in 6-well plates. Final RNA
interference (RNAi) concentrations were 50 nM. HCECs were transfected
following the RNAiMax reverse-transfection protocol using 2.5 l
RNAiMax transfection reagent per 6 ml of antibiotic-free medium and
150,000 cells/ml, with a final RNAi concentration of 10 nM in 6-cm dishes
(Corning; Primaria). After a 72-hour transfection, the cells were lysed in
RIPA lysis buffer with protease and phosphatase inhibitors (described
below).
Reagents. The EPHB4 receptor tyrosine kinase inhibitor (AZ12672857)
was a gift from J. Kettle (AstraZeneca). The EPHB4 inhibitor was dissolved in
dimethyl sulfoxide (DMSO) to achieve a stock concentration of 10 mM. Z-
Leu-Leu-Leu-al (MG132) (C2211), cycloheximide (CHX) (C7698), bafilo-
mycin A1 (BafA1) (B1793), poly-2-hydroxyethyl methacrylate (polyHEMA)
(P3932), and propidium iodide (PI) (P4170) were purchased from Sigma-
Aldrich and were used at the concentrations specified in the figures and leg-
ends.
Anchorage-independent growth on polyHEMA-coated plates. poly-
HEMA stock solution (10 mg/ml) was made by dissolving polyHEMA in
95% ethanol and shaking at 37°C until it was fully dissolved (6 h to over-
night). Black-sided, clear-bottom 96-well plates were coated with poly-
HEMA by evaporating 200l of the 10-mg/ml stock polyHEMA solution
in each well. Cells were plated in complete medium on the polyHEMA-
coated wells at a concentration of 2 104 cells/100 l 48 h posttransfec-
tion (as described above). Cell viability was measured according to the
manufacturer’s protocol using the CellTiter-Glo luminescent cell viability
assay (Promega). Specifically, this was done by adding 90 l of CellTiter-
Glo reagent, shaking for 2 min to lyse the cells, incubating at room tem-
perature for 10 min, and measuring the luminescence (Polarstar Optima).
TABLE 1 Sequences of individual siRNA duplexes
Target Item no. siRNA no.a Target sequence
hKSR1 J-003570 6 CAUCAUAGACAGCAGUUUA
7 GAGCAAGUCCCAUGAGUCU
8 GGAAUGAAGCGUGUCCUGA
9 AGAAAGAGGUGAUGAACUA
hEPHB4 D-003124 5 GGACAAACACGGACAGUAU
6 GUACUAAGGUCUACAUCGA
7 GGAGAGAAGCAGAAUAUUC
8 GCCAAUAGCCACUCUAACA
hMyc J-003282 23 ACGGAACUCUUGUGCGUAA
24 GAACACACAACGUCUUGGA
25 AACGUUAGCUUCACCAACA
26 CGAUGUUGUUUCUGUGGAA
a Manufacturer’s number for siRNA sequence.
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Cell viability assay. Cells (5,000/well) were transfected on white 96-
well plates. Transfections were done as described above but at a ratio of
1:25 for all of the reagents. At 0 and 72 h posttransfection, 10 l of ala-
marBlue (ThermoFisher Scientific) was robotically added to each well.
The plates were incubated at 37°C for 3 h, and fluorescence was measured
(Polarstar Optima).
Propidium iodide. Cells were assayed for apoptosis using the sub-G1
peak measured following PI staining. Prior to staining, all the medium in
each sample well was collected and placed in a 12- by 75-mm round-
bottom polystyrene tube (BD Falcon; 352054). The cells were washed
once with phosphate-buffered saline (PBS), the PBS was saved, and the
cells were subsequently treated with 0.25% trypsin for 5 to 10 min. The
saved medium was then used to resuspend the trypsin-treated cells from
the corresponding wells, which were collected and placed in the polysty-
rene tubes. The cells were pelleted by centrifugation for 5 min at 2,800 rpm
using an Immunofuge II (Baxter/Dade). The supernatant was aspirated,
and the cell pellets were resuspended in 2 ml of PBS and then pelleted
again by centrifugation for 3 min at 2,800 rpm. The PBS was aspirated,
and the cells were fixed in 2 ml of ice-cold 70% ethanol for at least 1 h at
20°C. The cells were then warmed to room temperature (15 min),
pelleted by centrifugation for 3 min, and then rehydrated in 2 ml of room
temperature PBS and incubated at 37°C for 15 min. The cells were then
pelleted, the PBS was aspirated, and the cells were resuspended in PI stain
overnight. Data were acquired using a Becton-Dickinson FACSCalibur
flow cytometer and analyzed using ModFit analysis software to detect a
sub-G1 peak of fluorescence.
Western blot analysis. Whole-cell lysate extracts were prepared in
radioimmunoprecipitation assay (RIPA) buffer composed of 50 mM Tris-
HCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sul-
fate, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 10 g/ml aprotinin, 10
g/ml leupeptin, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride
[PMSF]). Cytoplasmic and nuclear fractionations were performed using
NE-PER nuclear/cytoplasmic extraction reagents (Thermo Scientific;
78835) The protein concentration was determined using the Promega
bicinchoninic acid (BCA) protein assay. Samples were diluted in 1 sam-
ple buffer (5 stock; 313 mM Tris-HCl, pH 6.8, 10% SDS, 50% glycerol,
0.05% bromophenol blue) with 100 mM dithiothreitol (DTT) (20
stock; 2 M). SDS-PAGE was performed, and the membranes were blocked
in Odyssey PBS blocking buffer (LI-COR Biosciences; 927-40000) and
incubated in primary antibody (see below) overnight at 4°C. LI-COR
secondary antibodies (IRDye 800CW, 680LT, and 680RD) were diluted
1:5,000 to 1:10,000 in 0.1% Tris-buffered saline (TBS)–Tween 20 (TBST)
(for nitrocellulose) or 0.1% TBST plus 0.01% SDS (for polyvinylidene
difluoride [PVDF]). The membranes were imaged using the LI-COR
Odyssey.
Antibodies. Primary antibodies were diluted as follows: EPHB4
(monoclonal antibody [MAb] 265; a gift from Vasgene), 1:500, and
D1C7N (14960; Cell Signaling), 1:1,000; KSR1 (H-70; Santa Cruz),
1:1,000; 	-tubulin (B-5-1-2; Santa Cruz), 1:2,500; -actin (C-4; Santa
Cruz), 1:2,000; PGC1 (provided by A. Kralli, Scripps Research Institute),
1:5,000; c-Myc (5605; Cell Signaling), 1:1,000; poly(ADP-ribose) poly-
merase (PARP) (9542; Cell Signaling), 1:1,000; pERK (9106; Cell Signal-
ing), 1:1,000; ERK (9102; Cell Signaling), 1:1,000; pMEK (4694; Cell Sig-
naling), 1:1,000; MEK (9122; Cell Signaling), 1:1,000; LC3B (2775; Cell
Signaling), 1:1,000; p62/SQSTM1 (5114; Cell Signaling), 1:1,000; pro-
grammed cell death 4 (PDCD4) (D29C6) (9535; Cell Signaling), 1:1,000;
p4E-BP1 T70 (9455; Cell Signaling), 1:1,000; eukaryotic initiation factor
4A (eIF4A) (C32B4) (2013; Cell Signaling), 1:1,000; eIF4E (9742; Cell
Signaling), 1:1,000; peIF4E (S209) (9741; Cell Signaling), 1:1,000; eukary-
otic initiation factor 4E binding protein 1 (4E-BP1) (53H11) (9644; Cell
Signaling), 1:1,000.
RT-qPCR. RNA was harvested using 1 ml TriReagent (MRC; TR118)
and stored at80°C until extraction. The RNA was extracted according to
the manufacturer’s protocol, and the final RNA pellets were resuspended
in nuclease-free water. DNase digestion was performed (Qiagen; 79254),
and RNA cleanup was completed (Qiagen; 74106). The RNA was quanti-
fied using a NanoDrop 2000 (Thermo Scientific). Reverse transcription
(RT) was performed using iScript Reverse Transcription Supermix for
RT-quantitative PCR (qPCR) (Bio-Rad; 170-8840) with 1g of total RNA
per 20-l reaction mixture. RT-qPCR was performed using the primers
and conditions listed in Table 2. All the targets were amplified using
SsoAdvanced Universal SYBR green Supermix (Bio-Rad), with 40 cycles
of a 2-step program (95°C for 5 s; melting temperature [Tm] for 45 s) on an
MX3000P (Stratagene). The data were normalized using two of the fol-
lowing normalization genes: HPRT, -actin, and GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase). Analysis was performed according to
the q-base protocol, as previously published (41).
TCGA. mRNA expression was analyzed based on the transcriptome
sequencing (RNA-Seq) by expectation maximization (RSEM)-normal-
ized RNA-Seq values of primary tumor (n
 285) and normal solid tissue
(n
 41) samples, as well as patient-matched samples (n
 26), within The
Cancer Genome Atlas (TCGA) colon adenocarcinoma (COAD) data set.
The results were analyzed for statistical significance using unpaired and
paired Student’s t tests for the unpaired and patient-matched samples,
respectively.
Myc translation. Myc translation reporter constructs (pGML, phpL,
and phpmL) for luciferase assays were a gift from Anne Willis (Medical
Research Council, Leicester, United Kingdom) (42, 43). RNAi depletions
were performed in 6-well plates as described above. The following day, the
cells were transfected with 3 g of the translation vector and 1 g of the
pSV--galactosidase vector (Promega; E1081) using 10 l of Lipo-
fectamine 2000 (Invitrogen) per well. After 24 h, luciferase and -galac-
tosidase (-Gal) expression was assessed using the Dual-Light system
(Applied Biosciences; T1003) according to the manufacturer’s instruc-
tions. Briefly, cells were rinsed twice with PBS and lysed with lysis solution
(100 mM potassium phosphate, pH 7.8, 0.2% Triton X-100, 0.5 mM
DTT), and 10l of each lysate was added (in triplicate) to a 96-well plate.
Luminescence was measured (Polarstar Optima) for 1 s per well begin-
ning 1.5 s following injection. When quantifying basal translation from
each vector, luciferase expression was normalized to -galactosidase ex-
pression. When comparing the effect of KSR1 depletion on Myc transla-
tion, the luciferase signal was normalized to the protein input.
Statistical analyses. P values and 50% effective concentrations
(EC50s) were calculated using Prism software (GraphPad, La Jolla, CA). A
TABLE 2 Sequences of qPCR primers
Target Accession no.
Amplicon
size (bp) Exon(s) Tm (°C)
Primer (5=¡3=)
Forward Reverse
hPPARGC1B NM_001172699 102 12, 13 62 GAATATTTCAGTAAGCTGTCA GCCCAGATACACTGACTACG
hMyc NM_002467.4 119 3 58 GGCTCCTGGCAAAAGGTCA CTGCGTAGTTGTGCTGATGT
hKSR1 NM_014238.1 127 20, 21 60 AGTTTCTCCAGCATGTCCATC GAATGAAGCGTGTCCTGACT
hEPHB4 NM_004444 90 12, 13 62 AGCTGGATGACTGTGAACTG GCCCGTCATGATTCTCACA
hGAPDH NM_002046.1 111 2, 3 58 GGTGAAGGTCGGAGTCAACGG GAGGTCAATGAAGGGGTCATTG
hACTB NM_001101.1 59 4 60 ACCGAGCGCGGCTACAG CTTAATGTCACGCACGATTTCC
hHPRT1 NM_000194 128 6–8 60 GTATTCATTATAGTCAAGGGCATATCC AGATGGTCAAGGTCGCAAG
McCall et al.
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P value of less than 0.05 was considered statistically significant. The values
presented here are shown as means  standard deviations (SD) unless
otherwise noted. EC50s were calculated in Prism using an algorithm for
fitting nonlinear curves with variable slopes.
RESULTS
EPHB4 is required for human colon tumor cell survival. KSR1
regulates the oncogenic potential of activated Ras (14). Our labo-
ratory has recently shown that KSR1 also promotes anchorage-
independent growth and tumor maintenance in human colon tu-
mor cell lines (16). Importantly, we demonstrated that depletion
of KSR1 is selectively toxic to CRC cells compared to immortal-
ized, nontransformed HCECs. Using a gene expression signature
representing depletion of KSR1, we developed a high-throughput
screen called FUSION (19) to identify functional analogs of KSR1.
Details regarding the screen, gene signature, and FUSION have
been provided previously (16, 19). Based on unsupervised hierar-
chical clustering of reporter gene expression following RNAi-me-
diated depletions of individual genes, we found that knockdown
of EPHB4 clustered with the RNAi-mediated KSR1 depletion
(siKSR1) positive controls. We further visualized this relationship
by plotting Pearson correlation versus Euclidean distance similar-
ity metrics (Fig. 1A). Depletion of EPHB4 has a Euclidean distance
of 1.44 and a Pearson correlation of 0.88, and siEPHB4 (blue)
clusters with the siKSR1 (red) reference standards. Based on pre-
vious work demonstrating that gene expression-based signatures
can be used to represent the functional state of a cell (16, 19, 44,
45), the similarity of siKSR1- and siEPHB4-dependent gene ex-
pression signatures suggests that EPHB4 is likely to support colon
tumor cell survival similarly to KSR1.
EPHB4 expression is elevated in a variety of human cancers,
including cancers of the head and neck, prostate, bladder, ovaries,
large intestine, lung, brain, pancreas, and esophagus (46–54). We
analyzed the expression of EPHB4 in a panel of colon tumor cells
compared to its expression in HCECs. Western blotting revealed
that the EPHB4 protein is overexpressed in all colon tumor cell
lines tested (Fig. 1B). RT-qPCR analyses demonstrated that the
abundance of protein could not be entirely attributed to an over-
abundance of mRNA (Fig. 1C). While there was a trend toward
increased mRNA levels in all colon tumor cell lines compared to
HCECs, only SK-CO-1 cells showed a statistically significant dif-
ference. To evaluate the relevance of these findings in human tu-
mors, we examined EPHB4 gene expression in the colon adenocarci-
noma data set within TCGA and demonstrated that EPHB4 was
significantly increased at the mRNA level in human colon tumor
samples compared to normal solid-tissue samples (Fig. 1D). These
findings were consistent both using all available data (top) or using
only the patient-matched tumor and normal samples (bottom). In
fact, every patient-matched tumor demonstrated an increase in
EPHB4 expression relative to the normal sample.
Depletion of EPHB4 is selectively toxic to colon tumor cells.
Depletion of KSR1 is selectively toxic to colon tumor cells com-
pared to HCECs (16). To determine whether EPHB4, like KSR1, is
required for tumor cell survival, we measured viability, anchor-
age-independent proliferation, and apoptosis in two colon tumor
cell lines and HCECs following knockdown of KSR1 or EPHB4 by
RNAi. Cell proliferation was measured by alamarBlue cell viability
assay after 72 h of KSR1 or EPHB4 depletion. In HCT116 cells,
KSR1 and EPHB4 RNAi reduced cell proliferation compared to
controls by 81% and 71%, respectively (Fig. 2A), whereas in the
Caco2 cells, cell viability was decreased by 95% with KSR1 deple-
tion and 69% with depletion of EPHB4. Cell proliferation was
unaffected in the HCEC line. To measure anchorage-independent
growth, cell proliferation was measured on a polyHEMA-coated
plate (55, 56) using a CellTiter-Glo luminescent cell viability as-
say, as previously described (16). Following depletion of KSR1 or
EPHB4, growth under anchorage-independent conditions was re-
duced by 57% and 53% in HCT116 cells and 74% and 51% in
Caco2 cells, respectively (Fig. 2B). HCECs are unable to prolifer-
ate in an anchorage-independent environment and were not used
in this experiment. Validation of target knockdown was by
Western blotting (Fig. 2A and B). To determine if the reduced
cell viability under normal and anchorage-independent condi-
tions was due to increased apoptosis, PARP cleavage was as-
sessed by Western blotting following depletion of KSR1 and
EPHB4 in HCECs and HCT116 and Caco2 cells. HCECs
showed no PARP cleavage following target knockdown,
whereas HCT116 and Caco2 cells demonstrated PARP cleavage
upon KSR1 or EPHB4 depletion (Fig. 2C). These observations
show that KSR1 or EPHB4 is selectively required for colon
tumor cell survival and growth and suggest that without KSR1
or EPHB4, cells undergo apoptosis.
Downstream effectors of KSR1-dependent signaling in colon
tumor cell lines include the RAF/MEK/ERK kinase cascade and
the PGC1 family of transcriptional regulators (14–16, 57, 58). We
recently identified PGC1 as a key downstream effector of KSR1
in human colon tumor cells and showed that its expression is
required for colon cancer survival both in vitro and in vivo (16). To
determine whether EPHB4 disrupts either of these pathways, we
assessed MEK1/2 and ERK1/2 activation and total PGC1 protein
levels by Western blotting after 72 h of EPHB4 depletion in
HCT116 and Caco2 cells. We observed that depletion of EPHB4
did not affect MEK1/2 or ERK1/2 phosphorylation. However,
EPHB4 RNAi did suppress PGC1 levels (Fig. 2D). These data
indicate that, like KSR1, EPHB4 regulates PGC1.
Inhibition of EPHB4 kinase activity is selectively toxic to co-
lon tumor cells. Pharmacological targeting of EPHB4 is of clinical
interest (23, 24). One strategy for targeting EPHB4 is inhibition of
its kinase activity. To determine the extent to which inhibition of
the EPHB4 kinase, like RNAi-mediated EPHB4 depletion, is selec-
tively toxic to colon tumor cells, we measured viability in HCECs
and a panel of colon tumor cell lines treated for 72 h with increas-
ing doses of an EPHB4 kinase inhibitor, AZ12672857 (AZ2857)
(59). The EC50 for each cell line was determined from four inde-
pendent experiments using a nonlinear curve fitted with a variable
slope (Fig. 3A). HCECs (EC50 
 14 M) were less sensitive to
EPHB4 inhibition than HCT116 or Caco2 cells (EC50 
 3.2 M
and 2.6 M, respectively). The EC50s of three additional colon
tumor cell lines (SW480, DLD1, and SK-CO-1) are shown in the
table in Fig. 3A. HCECs tolerated doses up to 20 M (the highest
dose tested) without increasing the percentage of PI-stained cells
in the sub-G1 peak measured by flow cytometry (Fig. 3B). How-
ever, at the same dose, HCT116 and Caco2 cells had50% sub-G1
cells after 72 h of treatment with AZ2857. Taken together, these
data indicate that inhibition of EPHB4 decreases total ATP levels
as measured by the CellTiter-Glo cell viability assay in HCECs,
possibly through reduced growth or induction of senescence, but
that treatment with AZ2857 does not induce apoptosis. However,
in the tumor cell lines HCT116 and Caco2, treatment with
AZ2857 clearly reduces cell viability via induction of cell death.
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KSR1 protects EPHB4 from lysosome-dependent degrada-
tion. To assess the possible relationships between KSR1 and
EPHB4, KSR1 and EPHB4 were depleted by siRNA for 72 h in
HCT116 and Caco2 cells. The levels of KSR1 and EPHB4 proteins
(Fig. 4A) and mRNA (Fig. 4B) were measured by Western blotting
and RT-qPCR, respectively. Depletion of KSR1 resulted in a consis-
tent reduction in EPHB4 protein expression but not mRNA levels.
EPHB4 knockdown did not affect KSR1 protein or mRNA expres-
sion in either cell line. These observations suggest that KSR1 regulates
EPHB4 protein levels via a posttranscriptional mechanism.
KSR1 regulates proteins such as Myc and PGC1, which are
degraded by the proteasome (16, 60). Therefore, we tested
FIG 1 Genome-scale RNAi screen identifies EPHB4 as a KSR1-like effector. (A) Identification of EPHB4 as a KSR1-like effector using Pearson correlation and
Euclidean distance similarity metrics. (B and C) Western blot (B) and RT-qPCR (C) of EPHB4 levels in a panel of colon tumor cell lines and immortalized,
nontransformed HCECs. The RT-qPCR data are shown as means  SD. ****, P  0.0001 (matched one-way analysis of variance [ANOVA] and Dunnett’s
posttest). (D) EPHB4 gene expression (RNA-Seq) data from TCGA for unpaired primary colon tumors and normal solid-tissue samples (top) and primary
tumors and patient-matched normal solid-tissue samples (bottom). The median is indicated with a horizontal line in the interior of the box, the first and third
quartiles are represented by the ends of the box, and the ends of the whiskers mark the minimum and maximum values. The numbers (n) of samples analyzed
are shown. Unpaired results were analyzed for statistical significance using Student’s unpaired t test. ****,P 0.0001. Matched results were analyzed for statistical
significance using Student’s paired t test. ****,P 0.0001. The results shown here are, in whole or in part, based upon data generated by TCGA Research Network
(http://cancergenome.nih.gov/).
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whether KSR1 depletion induces proteasome-mediated degrada-
tion of EPHB4. HCT116 and Caco2 cells were depleted of KSR1
for 72 h and incubated with and without 10 M MG132 for the
final 6 h of knockdown. Treatment with MG132 was unable to
rescue the EPHB4 levels when KSR1 was depleted (Fig. 4C). Inhi-
bition of proteasomal degradation of Myc was used as a positive
control for MG132 treatment. In HCT116 cells without KSR1 de-
pletion, MG132 treatment increased EPHB4 expression, suggest-
FIG 2 EPHB4 promotes CRC survival by regulating PGC1. (A and B) The viability of HCECs and HCT116 and Caco2 cells was measured following RNAi of
KSR1 or EPHB4 under normal (A) and anchorage-independent (B) conditions by alamarBlue and CellTiter-Glo assays, respectively. (Left) The data are shown
as mean fluorescence intensity or relative light units (RLU) SD. ****, P 0.0001 (matched two-way ANOVA and Dunnett’s posttest for multiple compari-
sons). (Right) Target knockdown for the assays was assessed by Western blotting. Cont, control. (C) PARP cleavage following depletion of KSR1 or EPHB4. (D)
Western blot of the indicated proteins in HCT116 and Caco2 cells following RNAi of EPHB4.
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ing that EPHB4 degradation is partially mediated by the protea-
some in these cells but that the effect of KSR1 on EPHB4 stability
is independent of proteasome-mediated degradation.
A canonical method of RTK signal termination is downregu-
lation after ligand binding (61–63). Lysosome-mediated degrada-
tion of RTKs, including EPHB1, has been well documented (64–
66). We assessed whether EPHB4 degradation is mediated by the
lysosome and whether KSR1 stabilizes EPHB4 expression by sup-
pressing this degradation. KSR1 was depleted in HCT116 and
Caco2 cells for 72 h with and without treatment with 100 nM
BafA1, an inhibitor of autophagosome-lysosome fusion, for the
final 8 h of knockdown. Treatment with BafA1 alone increased the
expression of EPHB4 in both HCT116 and Caco2 cells (Fig. 4D).
Additionally, when cells were depleted of KSR1, treatment with
BafA1 rescued EPHB4 expression. Increased LC3BII and p62 ex-
pression were used as positive controls for BafA1 treatment.
Taken together, these data indicate that KSR1 stabilizes EPHB4 by
suppressing lysosome-mediated degradation.
KSR1 and EPHB4 regulate Myc and PGC1. Previous re-
search had demonstrated that Myc regulates PGC1 transcription
in renal cell carcinoma (34) and breast cancer (33) cells. There-
fore, we examined whether Myc regulates PGC1 in colon tumor
cell lines. In HCT116 and Caco2 cells, Myc was depleted with a
pool of siRNA; PGC1 protein levels were decreased with Myc
knockdown, as assessed by Western blotting (Fig. 5A). To deter-
mine if this effect was due to a single siRNA and was potentially an
off-target effect, the four siRNA duplexes that compose the pool
were assessed independently. Expression of PGC1 protein was
correlated with the degree of Myc knockdown (Fig. 5B). The pool
of all four siRNA duplexes was used in the remaining experiments.
Next, PGC1mRNA levels were measured by RT-qPCR following
depletion of Myc. In both HCT116 and Caco2 cells, Myc depletion
significantly decreased expression of PGC1 mRNA (Fig. 5C).
Expression of Myc is required for the formation of intestinal
crypts but is dispensable for homeostasis of the adult epithelium
(67). To evaluate the importance of Myc expression to CRC cell
viability, the tumor cell lines HCT116 and Caco2 and a nontrans-
formed colon epithelial cell line (HCEC) were transfected with
siRNA targeting Myc or a nontargeting siRNA. Cell viability was
assessed 72 h posttransfection. Depletion of Myc reduced cell via-
FIG 3 EPHB4 inhibitors are selectively toxic to colon tumor cell lines. (A) HCECs and Caco2, HCT116, SW480, DLD1, and SK-CO-1 cells were treated with
increasing doses of AZ12672857, and cell viability was measured by CellTiter-Glo at 72 h. Each data point represents the results of four independent experiments.
The data are presented as means standard errors of the mean (SEM). The data were normalized, and the EC50 for each cell line was calculated using an algorithm
for fitting a nonlinear curve with variable slope in GraphPad Prism. (B) HCECs and HCT116 and Caco2 cells were treated with increasing doses of AZ12672857.
The sub-G1 peak was quantified following PI staining and analysis by flow cytometry. The error bars indicate SD.
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bility in HCT116 (60%) and Caco2 (64%) cells but did not affect
proliferation in the HCECs (Fig. 5D), indicating that the tumor cells
are more reliant on the expression of Myc for cell growth. Validation
of target knockdown by Western blotting is also shown.
To determine whether KSR1 and EPHB4 regulate PGC1
through a Myc-dependent pathway, we assessed Myc and PGC1
protein levels following KSR1 or EPHB4 depletion in HCT116 and
Caco2 cells. In both cell lines, depletion of KSR1 or EPHB4 re-
sulted in diminished expression of Myc and PGC1 (Fig. 6A),
with EPHB4 depletion having the greatest effect on Myc levels. To
confirm that these data are not the result of a single siRNA, we
transfected the four individual siRNA duplexes for KSR1 (Fig. 6B,
top) and EPHB4 (bottom) into HCT116 cells and measured tar-
get, Myc, and PGC1 protein expression by Western blotting 72 h
posttransfection. With the exception of KSR1 siRNA 6, all the
individual duplexes sufficiently depleted the expression of their
targets, as well as Myc and PGC1. Due to its lack of target knock-
down, KSR1 siRNA duplex 6 was not used in the siKSR1 pool in
any experiment. Additionally, HCT116 and Caco2 cells were
treated with increasing doses of the EPHB4 kinase inhibitor,
AZ2857, for 72 h. Western blotting indicated that pharmacologi-
cal inhibition of EPHB4 decreases Myc and PGC1 protein levels,
similar to that seen with depletion using siRNA (Fig. 6C).
To assess whether EPHB4 also regulates PGC1mRNA levels,
FIG 4 KSR1 protects EPHB4 from lysosome-dependent degradation. KSR1 or EPHB4 was depleted in HCT116 and Caco2 cells for 72 h. (A) KSR1 and EPHB4
protein levels were assessed by Western blotting. (B) KSR1 and EPHB4 mRNA levels were measured by RT-qPCR. The data are shown as means SD. *,P 0.05;
***, P 0.001 (repeated-measures, one-way ANOVA with Dunnett’s posttest for multiple comparisons). (C) KSR1 was depleted in HCT116 and Caco2 cells for
72 h. The cells were treated with and without 10 M MG132 for the last 8 h of knockdown. The proteins were analyzed by Western blotting. Myc was used as a
positive control for MG132 treatment. (D) KSR1 was depleted in HCT116 and Caco2 cells for 72 h. The cells were treated with and without 100 nM BafA1 for the
last 8 h of knockdown. The proteins were analyzed by Western blotting. LC3B and p62/SQSTRM were used as positive controls for BafA1 treatment.
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HCT116 and Caco2 cells were transfected with siRNA targeting
EPHB4 (or a nontargeting siRNA) or treated with 10M AZ2857
for 72 h. Myc and PGC1 mRNA levels were measured by RT-
qPCR. Data from three biological replicates (each measured in
triplicate) are shown in Fig. 6D (siRNA) and E (EPHB4 inhibitor).
Depletion of EPHB4 by siRNA decreased Myc and PGC1mRNA
expression by 46% and 49% in HCT116 cells and 70% and 26%
(not significant) in Caco2 cells, respectively. Inhibition of EPHB4
with the kinase inhibitor AZ2857 consistently decreased the levels
of both Myc and PGC1mRNAs 70% and 45% in HCT116 cells
and 67% and 56% in Caco2 cells, respectively. Depletion of KSR1
did not affect Myc or PGC1 mRNA levels (Fig. 6D). These ob-
servations suggest that EPHB4 may regulate PGC1 transcription
in a Myc-dependent manner. Although EPHB4 was identified by
FUSION using KSR1 as a reference standard and the two proteins
share common downstream effectors (Myc and PGC1), these
data reveal that the mechanisms by which EPHB4 and KSR1 reg-
ulate Myc and PGC1 are not identical.
KSR1 and EPHB4 do not promote Myc stability. To test the
hypothesis that depletion of KSR1 or EPHB4 affects Myc levels by
regulating protein stability, we examined the turnover of Myc in
HCT116 and Caco2 cells following treatment with CHX with and
without RNAi of KSR1 or EPHB4. Representative immunoblots
of Myc in HCT116 cells after knockdown are shown in Fig. 7A.
Data from three independent experiments in each cell line were
quantified, and the half-life of Myc under each condition was
calculated using GraphPad Prism software. Depletion of KSR1
or EPHB4 did not change the rate of Myc turnover (Fig. 7B).
KSR1 promotes the translation ofMyc. Regulation of protein
synthesis is mediated by key inhibitors of translation, 4E-BP1 and
FIG 5 Myc regulates PGC1 in colon tumor cells. (A) Western blot following RNAi of Myc in HCT116 and Caco2 cells. (B) Myc and PGC1 protein expression
in HCT116 cells transfected with individual or pooled (all 4) Myc siRNA duplexes. (C) RNA levels of Myc and PGC1 were measured by RT-qPCR in HCT116
and Caco2 cells following RNAi of Myc. (D) Cell viability was measured by alamarBlue following depletion of Myc. The data are shown as means SD. *, P
0.05; **, P 0.01; ***, P 0.001 (paired, two-tailed t test[C] and matched, two-way ANOVA [D]).
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programmed cell death 4 (PDCD4) (reviewed in reference 68).
4E-BP1 sequesters eukaryotic initiation factor 4E (eIF4E) to in-
hibit translation. Phosphorylation of 4E-BP1 releases eIF4E and
derepresses protein synthesis (reviewed in reference 68). Simi-
larly, PDCD4 sequesters eukaryotic initiation factor 4A (eIF4A).
Phosphorylation of PDCD4 leads to its nuclear localization or
proteasome-mediated degradation (69). PDCD4 can be phos-
phorylated by p70 S6 kinase (S6K) or p90 ribosomal protein S6K
(RSK) (69, 70). 4E-BP1 and eIF4E regulate cap-dependent trans-
lation, while PDCD4 and eIF4A regulate both cap-dependent and
-independent translation (reviewed in reference 68).
To determine if KSR1 or EPHB4 affects the expression of these
key regulators of protein synthesis, KSR1 and EPHB4 were de-
pleted by siRNA for 48 h in HCT116 and Caco2 cells. In both cell
lines, depletion of KSR1 but not EPHB4 decreased 4E-BP1 and
eIF4E phosphorylation (Fig. 8A). This observation suggests that
depletion of KSR1 inhibits cap-dependent translation. Depletion
of KSR1 and not EPHB4 also increased the total levels of PDCD4
(Fig. 8A), suggesting that KSR1 may promote both cap-dependent
and cap-independent translation.
The potent role played by KSR1 in regard to key effectors of
translation led us to assess the role of KSR1 in the translation of
FIG 6 Inhibition of EPHB4 decreases Myc RNA and protein levels. (A and C) Myc and PGC1 protein levels were assessed by Western blotting following RNAi
of KSR1 or EPHB4 (A) or treatment with AZ2857, an EPHB4 inhibitor (C), in HCT116 and Caco2 cells. (B) Individual siRNA duplexes for KSR1 (top) and
EPHB4 (bottom) were transfected into HCT116 cells, and Myc and PGC1 protein expression was assessed by Western blotting. (D and E) RNA levels of Myc
and PGC1 were measured by RT-qPCR in HCT116 and Caco2 cells following RNAi of EPHB4 (D) or treatment with AZ2857 (E). The data are shown as
means SD. *, P 0.05; **, P 0.01 (paired, two-tailed t test).
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Myc proteins using luciferase reporter constructs containing the
Myc 5= untranslated region (UTR). The 5= UTR of Myc mRNA
contains an internal ribosome entry site (IRES) (42), and there-
fore, Myc is translated in a cap- and IRES-dependent manner.
Translation from the IRES element depends on eIF4A (helicase)
but is independent of eIF4E (cap binding protein) (71). To deter-
mine the relative contribution of IRES-dependent translation of
Myc to total Myc synthesis, HCT116 and Caco2 cells were trans-
fected with pGML (Myc 5= UTR), phpL (hairpin only), or phpmL
(hairpin-Myc 5= UTR) luciferase reporter constructs with a pSV-
-galactosidase vector for 24 h. Luciferase expression was normal-
ized to the -galactosidase expression in each well. IRES-depen-
dent translation comprises 32% and 14% of total Myc translation
in HCT116 and Caco2 cells, respectively (Fig. 8B).
To assess whether depletion of KSR1 affects translation via the
Myc 5= UTR, we first measured total translation of luciferase (cap
and IRES dependent) using the pGML reporter construct (43, 72).
The luciferase signal was normalized to total protein in each sam-
ple. Depletion of KSR1 decreased translation of Myc in HCT116
and Caco2 cells by 49% and 33%, respectively (Fig. 8C). Since
KSR1 also affected the expression of PDCD4, we also measured
the effect of KSR1 depletion on IRES-dependent translation of
Myc. Depletion of KSR1 decreased IRES-dependent Myc transla-
tion in HCT116 and Caco2 cells by 63% and 68%, respectively
(Fig. 8D).
DISCUSSION
We have identified a new pathway critical for colon tumor cell
survival impacted by effectors of Ras and Wnt signaling. Two
proteins, KSR1 and EPHB4, are required for increased Myc
protein expression in human colon tumor cells, which then
promotes the expression of its downstream effector, PGC1.
We recently showed that Ras-induced and KSR1-dependent
PGC1 upregulation promotes colon cancer survival in vitro
and in vivo (16). This effect is likely due, at least in part, to the
ability of this transcriptional coregulator to promote the ex-
pression of genes critical to the expansion of glycolytic and
oxidative metabolism (16, 33, 73). Here, we show that KSR1-
and EPHB4-dependent mechanisms increase Myc expression,
which drives PGC1 expression in colon tumor cell lines to
promote their survival.
These data highlight the utility of an unbiased RNAi screen and
FUSION analysis to identify vulnerabilities present in CRC cells
but not in nontransformed colon epithelial cells. The identifica-
tion of EPHB4 as a novel effector of Myc signaling prompted us to
evaluate the relationship between KSR1 and Myc and revealed that
EPHB4 and KSR1 promote PGC1 expression via increased Myc
mRNA expression and protein translation, respectively. While the
regulation of PGC1 by Myc has been detected previously in renal
cell carcinoma (34) and breast cancer cells (33), we show that this
pathway is critical for colon cancer cell survival. Taken together,
these data reveal that tumor cells in various cancers have a unique
dependence on Myc-dependent expression of PGC1 to promote
cell survival, which may be exploited in the development of new
cancer therapeutics.
Using KSR1 as a reference standard, we used FUSION (16, 19)
to identify the EPHB4 gene as a gene that is required for colon
FIG 7 KSR1 or EPHB4 depletion does not affect Myc stability in HCT116 or Caco2 cells. (A) Depletion of KSR1 or EPHB4 was performed for 72 h prior to
treatment with 100 g/ml CHX or vehicle for 0, 15, 30, 45, 60, or 75 min. Myc levels were assessed by Western blotting. (B) An assay was performed three times
in each cell line. Myc expression was quantified and normalized to -actin. The Myc half-life was calculated using nonlinear, one-phase decay (Y0 
 100;
plateau
 0) with automatic outlier elimination in GraphPad Prism. The error bars indicate SD.
McCall et al.
2256 mcb.asm.org September 2016 Volume 36 Number 17Molecular and Cellular Biology
tumor cell survival. The mechanistic role that EPHB4 plays in
cancer remains controversial. However, a preponderance of data
indicate that EPHB4 is overexpressed broadly in human cancers,
including cancers of the head and neck, prostate, bladder, ovaries,
large intestine, lung, brain, pancreas, and esophagus (46–54). Fur-
ther research has shown that the ablation or inhibition of EPHB4
in a number of cancer cell types reduces tumor cell viability, in-
cluding prostate (47), bladder (48), ovarian (49), colon (50), lung
FIG 8 KSR1 promotes the translation of Myc in HCT116 and Caco2 cells. (A) HCT116 and Caco2 cells were transfected with siRNA targeting KSR1 or EPHB4 or a
nontargeting siRNA (Cont) for 48 h. Protein expression levels were assessed by Western blotting. (B) HCT116 and Caco2 cells were transfected with pGML (Myc 5=
UTR), phpL (hairpin only), or phpmL (hairpin-Myc 5= UTR) luciferase reporter constructs with a pSV--galactosidase vector for 24 h. Luciferase expression was
normalized to -galactosidase expression in each well. The data are shown as technical replicates of a single biological replicate. (C) HCT116 and Caco2 cells were
depleted of KSR1 for 24 h and then transfected with pGML for an additional 24 h. Luciferase expression was normalized to total protein in each well. The data are shown
as means and SD. *, P 0.05; **, P 0.01 (paired, two-tailed t test). (D) HCT116 and Caco2 cells were depleted of KSR1 for 24 h and then transfected with phpmL for
an additional 24 h. Luciferase expression was normalized to total protein in each well. The data are shown as means and SD. *, P 0.05 (paired, two-tailed t test).
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(51), head and neck squamous cell carcinoma (74), and esopha-
geal (54) cancer. Additionally, patient data have shown that
EPHB4 levels negatively correlate with overall patient survival in
ovarian cancer and glioblastoma (49, 52).
Expression of EPHB2 and EPHB4 is regulated by Wnt/-
catenin signaling in human CRC (50, 75). -Catenin’s binding
partners, p300 and CBP, determine which gene is transcribed,
with p300 promoting EPHB2 expression and CBP promoting
EPHB4 (50). EPHB2 is present in the normal colon and EPHB4 is
expressed only when tumors arise (50). These data contrast with
studies showing that EPHB4 is expressed in human colonic crypts
and early CRC lesions (76), followed by promoter hypermethyl-
ation and epigenetic silencing in more advanced stages (77). Fur-
ther evidence indicated that EPHB4 expression is highest at the
bases of crypts, suggesting that it plays an important role in main-
taining the population of stem and progenitor cells located in that
region of the crypt (76). The repulsive interaction that occurs
when the ephrin-B2 ligand-expressing cells of the upper region of
the crypt come in contact with the EPHB4 receptor-expressing
cells located at the base of the crypt suggests that this expression
pattern may aid in compartmentalizing tumor cells and reducing
the dissemination of such cells, serving as a tumor suppressor (76,
78–80). While it is controversial, the majority of studies support
the idea that increased EPH forward signaling promotes cell seg-
regation and is primarily tumor suppressive, whereas reverse sig-
naling through the ephrin ligand is tumor promoting, driving
neoangiogenesis and invasion (79, 81). However, EPHB forward
signaling can also be cross-activated by fibroblast growth factor
and ERBB receptors, leading to noncanonical forward signaling
that promotes cell proliferation (24), thereby contributing to can-
cer growth.
We show that EPHB4 is overexpressed in a panel of colon tu-
mor cell lines and that, like KSR1, EPHB4 depletion via siRNA or
small-molecule inhibition is selectively toxic to colon tumor cells
compared to immortalized but nontransformed HCECs. The
mechanism of HCEC resistance to EPHB4 inhibition may result
from the fact that EPHB4 expression is minimal in the cell line and
the cells do not rely on its overexpression for survival. These data
are consistent with previous studies showing that EPHB4 is absent
in normal colon but was expressed in 102 human colorectal cancer
sections analyzed by both immunohistochemistry and RT-qPCR
(50).
Lysosomal degradation of RTKs is well documented (82).
Here, we show that EPHB4 is primarily degraded via the lysosome
and that KSR1 forestalls that degradation. Canonical lysosomal
RTK degradation occurs following activation of the receptor by its
respective ligand. However, ligand-independent receptor degra-
dation has been reported (83, 84). KSR1-dependent effects on
Myc and PGC1 are not simply due to KSR1 stabilizing EPHB4.
This prediction is based on the differential effects (transcriptional
versus posttranscriptional regulation of Myc expression) observed
with KSR1 and EPHB4 depletion. However, the observation that
KSR1 promotes the stability of an RTK may allude to a broader
mechanism by which KSR1 supports tumorigenesis.
Recent work from TCGA network discovered that, in a com-
prehensive examination of human colon and rectal cancers with
diverse anatomical origins and mutation statuses, changes in Myc
transcriptional targets were found in nearly 100% of the tumors
(6), suggesting an important role for Myc in CRC. While a prom-
ising target for CRC, Myc is a transcription factor and traditionally
considered “undruggable” (35, 85). Although there are new strat-
egies emerging to inhibit Myc, including interrupting key
dimerization events or DNA binding (35), finding additional or
alternative ways to target Myc protein expression or its down-
stream effectors may provide therapeutic benefits to many cancer
patients.
Our studies show that EPHB4 regulates Myc expression
through the promotion of mRNA levels. KSR1 does not share this
mechanism of action, which led us to examine alternative expla-
nations for its ability to increase Myc levels in human colon tumor
cells. Further analyses of posttranscriptional mechanisms revealed
that KSR1 promotes the translation of Myc protein. Myc transla-
tion can be initiated via cap-dependent and -independent (IRES-
dependent) mechanisms (42, 71). Our data suggest that KSR1 can
promote both mechanisms of Myc protein synthesis (Fig. 7C and
D). However, depletion of KSR1 also increases PDCD4 and sup-
presses the phosphorylation of 4E-BP1 (Fig. 7A), key inhibitors of
global translation. This observation raises the intriguing possibil-
ity that KSR1-dependent tumors preferentially upregulate global
protein synthesis in support of the transformed phenotype. Tu-
mors can develop an enhanced ability to promote cap-dependent
translation by overexpressing eIF4E or loss of 4E-BP (reviewed in
reference 86). However, during apoptosis, growth arrest, mitosis,
hypoxia, or amino acid starvation, cap-dependent translation is
suppressed and IRES-mediated translation is induced (72, 87). In
addition to Myc, IRES-dependent translation of mRNAs encod-
ing hypoxia-inducible factor 1	 (HIF1	), vascular endothelial
growth factor A (VEGFA), Bcl2, X-linked inhibitor of apoptosis
(XIAP), and p120 catenin, has been reported (reviewed in refer-
ence 86). It is important to note that we have tested only the ability
of KSR1 to promote IRES-mediated translation of Myc. However,
if KSR1 promotes IRES-mediated translation, future studies may
reveal transcripts that are selectively translated in a KSR1-depen-
dent manner to promote cancer cell survival during times of
stress.
Following hypoxia, PGC1mRNA is decreased in renal clear-
cell carcinoma cells by induction of MXI1, a repressor of Myc
activity (34). Subsequent work demonstrated that Myc regulates
Her2- and IGF1-dependent induction of PGC1 in breast cancer
cells (33). Our work indicates that Myc also mediates EPHB4- and
KSR1-dependent regulation of PGC1 expression. Combined
with these reports, our data suggest that tumor cells with diverse
origins find multiple ways to regulate Myc-driven PGC1 expres-
sion. The observation that KSR1 promotes 4EBP1 and decreases
PDCD4 expression suggests that increased Myc translation is a
consequence of a KSR1-dependent increase in global protein
translation. Translation is the most energy intensive activity of a
proliferating cell (88). This raises the intriguing possibility that the
increased energy demand in tumor cells demonstrating elevated
protein translation (68) is met by a coordinate increase in Myc-
dependent expression of PGC1 to expand the metabolic capacity
of the cells (73).
The identification of these relationships highlights an impor-
tant aspect of FUSION. Although the screen was intended to iden-
tify genes whose knockdown mimicked that of KSR1 depletion in
cancer cells whose transformation is driven by oncogenic Ras, it is
designed to select hits based on phenotype, which is not necessar-
ily limited to KSR1-specific pathways. Therefore, it may identify
critical effectors, such as EPHB4, whose inhibition has the same
effect as depletion of KSR1 but whose mechanism of action is
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different. Although the HCT116 cell line used in our screen ex-
presses RasG13D, our results demonstrate that the screen may
also identify vulnerabilities in tumor cells (e.g., Caco2 cells) that
do not express constitutively active Ras. This may lead to the iden-
tification of potential targets that are applicable in a wide variety of
cancer cell types.
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